AdaptHealth reported lower Q2 2025 revenue and profits, with challenges in Diabetes and Sleep Health segments. The company divested certain assets, reduced debt, and maintained cautious guidance for fiscal 2025.

The article highlights four undervalued stocks under $10 with significant growth potential across digital advertising, home healthcare, energy infrastructure, and social media sectors, each offering potential upside between 43-55%.

The article highlights three undervalued stocks under $10 - AdaptHealth, ADT, and Olo - that have strong growth potential and attractive fundamentals.

AdaptHealth, a home healthcare services company, reported weaker-than-expected Q3 results, missing analyst estimates for revenue and earnings. The company also reduced its full-year guidance for revenue and adjusted EBITDA, citing growth opportunities and investments. However, it lifted its 2024 free cash flow guidance.

KARL STORZ is set to acquire all of the outstanding shares of Asensus Surgical (ASXC) for $0.35 per share in cash, making Asensus a subsidiary of KARL STORZ.

AdaptHealth (NASDAQ:AHCO) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 1 0 0 0 Analysts have recently evaluated AdaptHealth and provided 12-month price targets. The average target is $13.0, accompanied by a high estimate of $13.00 and a low estimate of $13.00. Surpassing the previous average price target of $11.00, the current average has increased by 18.18%. Decoding Analyst Ratings: A Detailed Look The standing of AdaptHealth among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target David Macdonald Truist Securities Maintains Buy $13.00 $13.00 Ben Hendrix RBC Capital Maintains Outperform $13.00 - Whit Mayo UBS Raises Buy $13.00 $9.00 David Macdonald Truist Securities Raises Buy $13.00 $11.00 Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AdaptHealth. This information offers a snapshot of how analysts perceive ...Full story available on Benzinga.com

AdaptHealth (AHCO) delivered earnings and revenue surprises of -66.67% and 2.78%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 9.03% and 5.87%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Philips' (PHG) first-quarter results benefit from strong momentum across the Diagnosis & Treatment and Personal Health businesses. However, softness in the Connected Care business is a concern.

AHCO vs. BSX: Which Stock Is the Better Value Option?

Here is how AdaptHealth Corp. (AHCO) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.

The company published some very good news from the lab, although it wasn't so encouraging for smaller rivals.